Duchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Scope of the Report:
This report focuses on the Duchenne Muscular Dystrophy in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, Southeast Asia, India and Australia. This report categorizes the market based on manufacturers, countries/Regions, type and application.

Market Segment by Manufacturers, this report covers
PTC Therapeutics
Sarepta Therapeutics
Bristol-Myers Squibb
ITALFARMACO
BioMarin
Daiichi Sankyo
Solid Biosciences
Summit Therapeutics
FibroGen
NS Pharma
Pfizer
ReveraGen BioPharma
Wave Life
Genethon
Santhera Pharmaceuticals

Market Segment by Countries, covering
China
Japan
Korea
Taiwan
Southeast Asia
India
Australia

Market Segment by Type, covers
Deflazacort
Prednisone
Others

Market Segment by Applications, can be divided into
Male
Female

There are 19 Chapters to deeply display the Asia-Pacific Duchenne Muscular Dystrophy market.

Chapter 1, to describe Duchenne Muscular Dystrophy Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;

Chapter 2, to analyze the manufacturers of Duchenne Muscular Dystrophy, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the Asia-Pacific market by countries, covering China, Japan, Korea, Southeast Asia, Taiwan, India and Australia, with sales, price, revenue and market share of Duchenne Muscular Dystrophy, for each country, from 2013 to 2018;

Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type, application, from 2013 to 2018;

Chapter 7, 8, 9, 10, 11, 12 and 13 to analyze the key countries by manufacturers, Type and Application, covering 7 Regin, with sales, revenue and market share by manufacturers, types and applications;

Chapter 14, Duchenne Muscular Dystrophy market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2018 to 2023;

Chapter 15, to analyze the manufacturing cost, key raw materials and manufacturing process, etc.

Chapter 16, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);

Chapter 17, to describe sales channel, distributors, traders, dealers, etc.

Chapter 18 and 19, to describe the research findings and conclusion, appendix, methodology and data source.